SCHEMBL13081086

SCHEMBL13081086

Cc1cc(C)c(/C=C2\C(=O)Nc3ccc(Br)cc32)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 10/20 1.00
KDR P35968 5/20 0.77
PDPK1 O15530 2/20 0.77
PDGFRB P09619 4/20 0.76
FLT3 P36888 4/20 0.73
ALK Q9UM73 4/20 0.73
FGFR1 P11362 3/20 0.70
CSF1R P07333 2/20 0.70
SRC P12931 2/20 0.70
FLT1 P17948 2/20 0.70
FGFR3 P22607 2/20 0.70
MAPK1 P28482 2/20 0.70
FLT4 P35916 2/20 0.70
ABL1 P00519 2/20 0.70
NTRK1 P04629 2/20 0.70
PLK4 O00444 2/20 0.70
MEN1 O00255 1/20 0.70
NPC1 O15118 1/20 0.70
GMNN O75496 1/20 0.70
USP2 O75604 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859701 0.90 RET (0.81) RETKDRPDPK1PDGFRBFLT3
SCHEMBL6691877 0.90 RET (0.81) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5203211 0.87 PDPK1 (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5478517 0.87 PDPK1 (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL19979 0.84 RET (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL19978 0.84 RET (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5475962 0.84 PDGFRB (0.81) RETKDRPDPK1PDGFRBFLT3
SCHEMBL31726696 0.84 RET (0.76) RETKDRPDPK1PDGFRBFLT3
SCHEMBL29394706 0.84 RET (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL4416658 0.84 RET (1.00) RETKDRPDPK1PDGFRBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 US disclosed
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 US disclosed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES MAP1LC3B, MAP1LC3A, SQSTM1 RET 3313/4885KDR 2776/4885PDPK1 693/4885
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 RET 4729/4885KDR 3586/4885PDPK1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.